Credit: Peter Cooper / Flickr
Chickens that are genetically modified to produce human proteins in their eggs can offer a cost-effective method of producing certain types of drugs, research suggests.
The study—which has initially focused on producing high quality proteins for use in scientific research—found the drugs work at least as well as the same proteins produced using existing methods.
High quantities of the proteins can be recovered from each egg using a simple purification system and there are no adverse effects on the chickens themselves, which lay eggs as normal.
Researchers say the findings provide sound evidence for using chickens as a cheap method of producing high quality drugs for use in research studies and, potentially one day, in patients.
"We are not yet producing medicines for people, but this study shows that chickens are commercially viable for producing proteins suitable for drug discovery studies and other applications in biotechnology," says professor Helen Sang, of the Roslin Institute.
Eggs are already used for growing viruses that are used as vaccines, such as the flu jab.
This new approach is different because the therapeutic proteins are encoded in the chicken’s DNA and produced as part of the egg white.
The team initially focused on two proteins that are essential to the immune system and have therapeutic potential—a human protein called IFNalpha2a, which has powerful antiviral and anti-cancer effects, and the human and pig versions of a protein called macrophage-CSF, which is being developed as a therapy that stimulates damaged tissues to repair themselves.
Just three eggs were enough to produce a clinically relevant dose of the drug. As chickens can lay up to 300 eggs per year, researchers say their approach could be more cost-effective than other production methods for some important drugs.
Researchers say they haven’t produced medicines for use in patients yet but the study offers proof-of-principle that the system is feasible and could easily be adapted to produce other therapeutic proteins.
"These recent findings provide a promising proof of concept for future drug discovery and potential for developing more economical protein-based drugs," says Dr Ceri Lyn-Adams, head of Science Strategy, Bioscience for Health, BBSRC.
Protein-based drugs, which include antibody therapies such as Avastin and Herceptin, are widely used for treating cancer and other diseases.
For some of these proteins, the only way to produce them with sufficient quality involves mammalian cell culture techniques, which are expensive and have low yields. Other methods require complex purification systems and additional processing techniques, which raise costs.
Scientists have previously shown that genetically modified goats, rabbits, and chickens can be used to produce protein therapies in their milk or eggs.
The researchers say their new approach is more efficient, produces better yields, and is more cost-effective than these previous attempts.
Dr Lissa Herron, who is leading the commercialization of this research at Roslin Technologies, said the team was excited to develop the technology to its full potential. She said it offers hope for research in animal health as well as human therapeutics.
The study was carried out at the University of Edinburgh’s Roslin Institute and Roslin Technologies, a company set up to commercialise research at The Roslin Institute.
The research is published in BMC Biotechnology. The Roslin Institute receives strategic funding from the Biotechnology and Biological Sciences Research Council.